Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation reports business developments as a global life sciences company focused on bioprocessing technologies and systems used in manufacturing biological drugs. Its updates center on Filtration and Fluid Management, Chromatography, Process Analytics and Proteins, serving biopharmaceutical drug developers, CDMOs and other life science customers.
Recurring announcements include quarterly and annual financial results, financial guidance, organic revenue measures, margin commentary, product and support infrastructure such as Repligen Training & Innovation Centers and OPUS pre-packed chromatography columns, investor conference participation, regional customer support initiatives and board or senior finance governance changes.
Repligen (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, will participate in the William Blair 46th Annual Growth Stock Conference in Chicago.
President and CEO Olivier Loeillot will present a company overview on June 3 at 10:40 a.m. CT, with a live and replay webcast via the Investor Relations website.
Repligen (NASDAQ:RGEN) released its 2025 Corporate Sustainability Report, themed “Driving Sustainable Growth Together,” detailing progress across six impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success.
Highlights include 100% renewable electricity for U.S. and European manufacturing, a first enterprise-level Double Materiality Assessment aligned with ESRS, expanded Board sustainability oversight via the Audit Committee, new Human Rights and Sustainability & ESG policies, and a 14% reduction in global water withdrawals year-over-year.
Repligen (NASDAQ:RGEN) will present at the Bank of America Securities 2026 Global Healthcare Conference in Las Vegas on May 12-14, 2026. CFO Jason Garland will take part in an analyst-led discussion on May 12 at 10:00am PT.
A live webcast will be available on Repligen's Investor Relations website with a limited-time replay following the event.
Repligen (NASDAQ:RGEN) reported Q1 2026 revenue of $194 million, up 15% reported and 11% organic year‑over‑year, GAAP EPS of $0.15 and adjusted EPS of $0.48. The company reiterated FY26 organic revenue growth guidance of 9%–13% and raised adjusted diluted EPS guidance to $1.97–$2.05. Cash and marketable securities were $785 million at March 31, 2026. Corporate moves included a China OEM partnership, a Transformation Office launch, and the divestiture of Polymem (divestiture completed March 30, 2026).
Repligen (NASDAQ:RGEN) will report first quarter 2026 financial results on Tuesday, May 5, 2026. The company will issue a press release before market open and host a conference call at 8:00 a.m. ET to discuss results for the quarter ended March 31, 2026.
The call is accessible via toll-free dial-ins, meeting ID 931163466, and a live webcast on the company Investor Relations website; a replay will be archived afterwards.
Repligen (NASDAQ:RGEN) opened a new Repligen Training & Innovation Center (RTIC) at its OPUS pre-packed chromatography manufacturing site in Breda, Netherlands, on April 15, 2026. The Breda RTIC is the company’s third global center, joining Waltham and Tokyo, and showcases upstream, downstream, analytical and fluid management technologies.
The facility offers product exhibits, demonstration areas, hands-on workshops and pre-/post-sales customer support to strengthen global customer proximity and technical training.
Repligen (NASDAQ:RGEN) will participate in three investor conferences in March 2026: Leerink Global Healthcare (Mar 8–11), Barclays Global Healthcare (Mar 10–12) and KeyBanc Virtual Healthcare Forum (Mar 17–18). Executives Jason Garland and Olivier Loeillot will take part in analyst-led discussions on March 10–11 and March 18, with live webcasts for Leerink and KeyBanc available on the company investor relations website and replayable for a limited time.
Repligen (NASDAQ:RGEN) reported Q4 2025 revenue of $198M (up 18% reported, 14% organic) and full-year 2025 revenue of $738M (up 16% reported, 14% organic non-COVID). GAAP net income for FY2025 was $49M, adjusted net income was $97M, and cash plus marketable securities totaled $768M.
For 2026 the company guided to $810M–$840M revenue, 9%–13% organic growth, and adjusted operating margin expansion of ~150 basis points at the midpoint.
Repligen (NASDAQ:RGEN) will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. A press release will be issued before market open and management will host a conference call at 8:30 a.m. ET to discuss results for periods ended December 31, 2025.
The live call is toll-free at (800) 715-9871 (U.S.) or (646) 307-1963 (international) with no passcode. A webcast and subsequent replay will be available in the company Investor Relations section of the website.
Repligen (NASDAQ: RGEN) announced that Dr. Martin D. Madaus was elected Chair of the Board effective March 13, 2026, as Executive Chair Tony Hunt retires from the Board on that date and will remain as an advisor through March 2027. Dr. Madaus has served as a Repligen director since February 2023 and brings 36 years of industry experience, including five years as Chairman, President and CEO of Millipore and involvement in its 2010 acquisition by Merck KGaA. Dr. Madaus also serves on the boards of Azenta and Hologic and holds a D.V.M. and Ph.D. from universities in Germany.